Skip to main content
. Author manuscript; available in PMC: 2021 Jul 10.
Published in final edited form as: Cancer Res. 2020 Apr 17;80(12):2586–2598. doi: 10.1158/0008-5472.CAN-19-2660

Figure 3. Angpt2 knockdown in tumor cells does not impact immune cell infiltration.

Figure 3

(A-B) FACS-based immune analysis was performed control and Angpt2 knockdown RET primary tumors on day 14 after tumor implantation. Shown are the quantitation of tumor infiltrating lymphoid (A) and myeloid cells (B) (n=9-11; mean ± SD). All comparisons were rendered non-significant by Mann Whitney U test.